Working Paper |
File Downloads |
Abstract Views |
Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
A Breath of Fresh Air? Firm Type, Scale, Scope and Selection Effects in Drug Development |
0 |
0 |
0 |
0 |
1 |
1 |
3 |
219 |
A Breath of Fresh Air? Firm types, scale, scope and selection effects in drug development |
0 |
0 |
0 |
52 |
0 |
0 |
3 |
228 |
A powerful test of mean stationarity in dynamic models for panel data: Monte Carlo evidence |
0 |
0 |
0 |
76 |
0 |
0 |
1 |
115 |
An LM test for the mean stationarity assumption in dynamic panel-data models |
0 |
0 |
2 |
37 |
0 |
0 |
6 |
115 |
Autocorrelation and masked heterogeneity in panel data models estimated by maximum likelihood |
0 |
0 |
0 |
11 |
0 |
0 |
2 |
96 |
Dinamiche di mercato e intensità della concorrenza di prezzo nel segmento dei farmaci off patent. La posizione dell'Italia nel contesto europeo |
0 |
0 |
1 |
56 |
0 |
0 |
3 |
189 |
Dynamic Competition in Pharmaceuticals: Patent Expiry, Generic Penetration, and Industry Structure |
1 |
1 |
2 |
150 |
2 |
2 |
5 |
513 |
Everything You Always Wanted to Know about Inventors (But Never Asked): Evidence from the PatVal-EU Survey |
0 |
0 |
0 |
136 |
0 |
0 |
1 |
675 |
Everything you Always Wanted to Know about Inventors (but Never Asked): Evidence from the PatVal-EU Survey |
0 |
0 |
1 |
512 |
0 |
0 |
5 |
1,652 |
Exploiting Information from Singletons in Panel Data Analysis: A GMM Approach |
0 |
0 |
0 |
17 |
0 |
0 |
5 |
31 |
Exploring the nexus between appropriability and productivity in highly innovative and globalized companies |
0 |
1 |
2 |
2 |
1 |
2 |
11 |
11 |
Generici vs. Branded: confronto internazionale su prodotti off-patent rimborsati dal SSN |
0 |
0 |
0 |
16 |
0 |
0 |
1 |
98 |
Identification of linear panel data models when instruments are not available |
0 |
0 |
0 |
60 |
0 |
0 |
0 |
153 |
Il Decreto DL 15/04/2002, n. 63 sul Contenimento della Spesa Farmaceutica - Impatto sull'Industria e Distorsioni nel Funzionamento del Mercato |
0 |
0 |
0 |
14 |
0 |
0 |
2 |
113 |
Il prezzo di riferimento nel quadro regolatorio del mercato farmaceutico |
0 |
0 |
0 |
23 |
0 |
0 |
5 |
141 |
Improving GMM efficiency in dynamic models for panel data with mean stationarity |
0 |
0 |
0 |
80 |
0 |
0 |
3 |
110 |
International Cooperation in Pharmaceutical Research |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
9 |
International Cooperation in Pharmaceutical Research |
0 |
0 |
0 |
51 |
0 |
0 |
0 |
170 |
La spesa farmaceutica pubblica - Analisi degli ultimi anni e indicazioni per una nuova politica economica |
0 |
0 |
0 |
17 |
0 |
0 |
1 |
74 |
La spesa farmaceutica territoriale convenzionata: il modello FarmaRegio per l'analisi della variabilità regionale |
0 |
0 |
1 |
16 |
0 |
0 |
2 |
119 |
Medical Devices Competitiveness and Impact on Public Health Expenditure |
1 |
1 |
2 |
190 |
4 |
4 |
7 |
774 |
Medical Devices: Competitiveness and Impact on Public Health Expenditure |
0 |
0 |
2 |
33 |
0 |
1 |
5 |
178 |
Moment Conditions and Neglected Endogeneity in Panel Data Models |
0 |
0 |
0 |
51 |
0 |
0 |
0 |
128 |
Negative variance estimates in panel data models |
0 |
1 |
3 |
88 |
1 |
3 |
6 |
415 |
Nuove politiche per l'innovazione nel settore delle scienze della vita |
0 |
0 |
1 |
7 |
0 |
0 |
1 |
97 |
Patent Disclosure and R&D Competition in Pharmaceuticals |
0 |
0 |
0 |
117 |
1 |
3 |
6 |
321 |
Patent Disclosure and R&D Competition in Pharmaceuticals |
0 |
0 |
1 |
110 |
0 |
1 |
2 |
194 |
Patent Value and R&D Competition |
0 |
0 |
0 |
2 |
0 |
0 |
0 |
106 |
R&D and market size: who benefits from orphan drug regulation? |
0 |
0 |
1 |
76 |
0 |
0 |
3 |
194 |
R&D, Within and Between Patent Competition in the Pharmaceutical Industry |
0 |
0 |
2 |
174 |
0 |
0 |
4 |
374 |
Simulation-based estimation of Tobit model with random effects |
0 |
0 |
0 |
140 |
0 |
2 |
3 |
489 |
The Identification of Time-Invariant Variables in Panel Data Model: Exploring the Role of Science in Firms’ Productivity |
1 |
2 |
5 |
25 |
1 |
2 |
18 |
37 |
The Joint Estimate of Singleton and Longitudinal Observations: a GMM Approach for Improved Efficiency |
0 |
0 |
0 |
12 |
0 |
0 |
0 |
38 |
The Sustainability of European Health Care Systems: Beyond Income and Ageing |
0 |
0 |
0 |
3 |
0 |
0 |
1 |
45 |
The Sustainability of European Health Care Systems: Beyond Income and Ageing |
0 |
0 |
1 |
59 |
0 |
0 |
1 |
199 |
The Value of Failures in Pharmaceutical R&D |
0 |
0 |
1 |
33 |
0 |
1 |
4 |
149 |
The productivity crisis in pharmaceutical R&D |
0 |
0 |
1 |
179 |
0 |
1 |
4 |
511 |
Total Working Papers |
3 |
6 |
29 |
2,625 |
11 |
23 |
124 |
9,080 |